Harel Insurance Investments & Financial Services Ltd. Cuts Stock Holdings in AstraZeneca PLC $AZN

Harel Insurance Investments & Financial Services Ltd. reduced its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 77.3% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,440 shares of the company’s stock after selling 4,910 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in AstraZeneca were worth $101,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Accuvest Global Advisors purchased a new stake in AstraZeneca during the 2nd quarter worth approximately $206,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors grew its position in shares of AstraZeneca by 13.4% in the second quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 22,834 shares of the company’s stock valued at $1,596,000 after purchasing an additional 2,700 shares in the last quarter. AMG National Trust Bank grew its position in shares of AstraZeneca by 867.8% in the second quarter. AMG National Trust Bank now owns 35,694 shares of the company’s stock valued at $2,494,000 after purchasing an additional 32,006 shares in the last quarter. Simon Quick Advisors LLC grew its position in shares of AstraZeneca by 9.4% in the second quarter. Simon Quick Advisors LLC now owns 8,720 shares of the company’s stock valued at $609,000 after purchasing an additional 751 shares in the last quarter. Finally, Assetmark Inc. grew its position in shares of AstraZeneca by 10.3% in the second quarter. Assetmark Inc. now owns 291,363 shares of the company’s stock valued at $20,360,000 after purchasing an additional 27,100 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Trading Down 0.8%

Shares of AstraZeneca stock opened at $81.72 on Tuesday. The firm has a market capitalization of $253.45 billion, a price-to-earnings ratio of 30.72, a PEG ratio of 1.52 and a beta of 0.36. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $86.57. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. The stock has a 50 day moving average of $81.17 and a 200 day moving average of $75.18.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Berenberg Bank set a $97.00 price target on AstraZeneca in a research report on Wednesday, July 9th. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Finally, Jefferies Financial Group started coverage on AstraZeneca in a research report on Monday, October 27th. They issued a “buy” rating for the company. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, AstraZeneca has an average rating of “Moderate Buy” and an average target price of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.